发现一种用于治疗代谢功能障碍相关脂肪性肝病的选择性细胞色素P450 4A抑制剂。 - Suppr

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.

作者信息

Lee Minji, Son Myung Jin, Hong Sin-Hyoung, Ryu Jae-Sung, Min Ji-Hyeon, Lee Dong-Eon, Lee Ji Hoon, Kim Nam Doo, Park Shi-Young, Kim Darong, Joo Jeongmin, Kwak Jisung, Kim Kook Hwan, Lee Yong-Ho, Keum Byeong-Rak, Song Hyun Seok, Jung Youngae, Kim Koon Soon, Kim Gun-Hwa

机构信息

Digital Omics Research Center, Korea Basic Science Institute (KBSI), Cheongju, Republic of Korea.

Stem Cell Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Republic of Korea.

出版信息

Clin Transl Med. 2024 Oct;14(10):e1816. doi: 10.1002/ctm2.1816.

DOI:10.1002/ctm2.1816

PMID:39367660

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11452733/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f79b/11452733/92f52034dd21/CTM2-14-e1816-g001.jpg

相似文献

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.发现一种用于治疗代谢功能障碍相关脂肪性肝病的选择性细胞色素P450 4A抑制剂。

Clin Transl Med. 2024 Oct;14(10):e1816. doi: 10.1002/ctm2.1816.

NAFLD - A rising metabolic disease.非酒精性脂肪性肝病——一种日益常见的代谢性疾病。

Mol Metab. 2021 Aug;50:101274. doi: 10.1016/j.molmet.2021.101274. Epub 2021 Jul 2.

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.代谢相关脂肪性肝病患者中胰高血糖素样肽-1 受体激动剂疗效的比较：更新的系统评价和荟萃分析。

Front Endocrinol (Lausanne). 2021 Feb 16;11:622589. doi: 10.3389/fendo.2020.622589. eCollection 2020.

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).随着我们从单纯性非酒精性脂肪性肝病（NAFLD）时代过渡到代谢相关脂肪性肝病（DAFLD）时代，NAFLD 取得了进展。

Metabolism. 2020 Oct;111S:154318. doi: 10.1016/j.metabol.2020.154318. Epub 2020 Jul 21.

Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway.乌索苷 J 通过调节 AMPK/AKT 信号通路改善代谢紊乱和非酒精性脂肪性肝病。

Pharmacol Res. 2021 Jan;163:105298. doi: 10.1016/j.phrs.2020.105298. Epub 2020 Nov 18.

Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.植物源疗法治疗代谢功能障碍相关脂肪性肝病。

Int J Mol Sci. 2024 May 21;25(11):5571. doi: 10.3390/ijms25115571.

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).单酰甘油酰基转移酶 2（MGAT2）抑制剂治疗代谢疾病和非酒精性脂肪性肝炎（NASH）。

J Med Chem. 2018 Nov 21;61(22):9879-9888. doi: 10.1021/acs.jmedchem.8b00864. Epub 2018 Jul 17.

Evolving liver disease insights from NAFLD to MASLD.从非酒精性脂肪性肝病到代谢相关性脂肪性肝病的肝脏疾病进展见解。

Trends Endocrinol Metab. 2024 Aug;35(8):683-686. doi: 10.1016/j.tem.2024.02.012. Epub 2024 Feb 29.

[Clinical status and challenges of new drugs for metabolic dysfunction-associated fatty liver disease].[代谢功能障碍相关脂肪性肝病新药的临床现状与挑战]

Zhonghua Gan Zang Bing Za Zhi. 2024 Apr 20;32(4):300-302. doi: 10.3760/cma.j.cn501113-20240226-00096.

Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis.山奈酚在代谢性疾病中的疗效：在糖尿病、肥胖症、非酒精性脂肪性肝病、脂肪性肝炎和动脉粥样硬化中的作用机制。

Biomed Pharmacother. 2024 Jun;175:116694. doi: 10.1016/j.biopha.2024.116694. Epub 2024 May 6.

引用本文的文献

Arachidonic acid metabolism in metabolic dysfunction-associated steatotic liver disease and liver fibrosis.代谢功能障碍相关脂肪性肝病和肝纤维化中的花生四烯酸代谢

Hepatol Commun. 2025 Aug 29;9(9). doi: 10.1097/HC9.0000000000000802. eCollection 2025 Sep 1.

本文引用的文献

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.代谢相关脂肪性肝病新定义：国际专家共识声明。

J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8.

CYP4A11 is involved in the development of nonalcoholic fatty liver disease via ROS‑induced lipid peroxidation and inflammation.CYP4A11 通过 ROS 诱导的脂质过氧化和炎症参与非酒精性脂肪性肝病的发生。

Int J Mol Med. 2020 Apr;45(4):1121-1129. doi: 10.3892/ijmm.2020.4479. Epub 2020 Jan 28.

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.MAFLD：代谢相关脂肪性肝病的共识驱动命名建议。

Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312. Epub 2020 Feb 8.

Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model.在一种新型多细胞器官型肝脏模型中，靶向CYP4A可减轻肝脏脂肪变性。

J Biol Eng. 2019 Aug 8;13:69. doi: 10.1186/s13036-019-0198-8. eCollection 2019.

Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids.扩增型人多能干细胞来源的肝样类器官的生成。

J Hepatol. 2019 Nov;71(5):970-985. doi: 10.1016/j.jhep.2019.06.030. Epub 2019 Jul 9.

Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH.用动物模型提出正确的问题：甲硫氨酸和胆碱缺乏模型在预测人类 NASH 药物不良反应中的作用。

Toxicol Sci. 2018 Jan 1;161(1):23-33. doi: 10.1093/toxsci/kfx253.

Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis.细胞色素P450ω-羟化酶4A14基因的缺失可减轻肝脏脂肪变性和纤维化。

Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3181-3185. doi: 10.1073/pnas.1700172114. Epub 2017 Mar 7.

Inhibition of CYP4A reduces hepatic endoplasmic reticulum stress and features of diabetes in mice.抑制 CYP4A 可减少肝内质网应激和糖尿病的特征在小鼠。

Gastroenterology. 2014 Oct;147(4):860-9. doi: 10.1053/j.gastro.2014.06.039. Epub 2014 Jun 28.

CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.CYP4 酶作为潜在的药物靶点：关注酶的多样性、诱导剂和抑制剂，以及对 20-羟二十碳四烯酸（20-HETE）合酶和脂肪酸 ω-羟化酶活性的治疗调节。

Curr Top Med Chem. 2013;13(12):1429-40. doi: 10.2174/15680266113139990110.

IRE1 signaling affects cell fate during the unfolded protein response.肌醇需求酶1（IRE1）信号通路在未折叠蛋白反应过程中影响细胞命运。

Science. 2007 Nov 9;318(5852):944-9. doi: 10.1126/science.1146361.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Discovery of a selective cytochrome P450 4A inhibitor for the treatment of metabolic dysfunction-associated fatty liver disease.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献